1. Home
  2. CTKB vs CTMX Comparison

CTKB vs CTMX Comparison

Compare CTKB & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • CTMX
  • Stock Information
  • Founded
  • CTKB 1990
  • CTMX 2008
  • Country
  • CTKB United States
  • CTMX United States
  • Employees
  • CTKB N/A
  • CTMX N/A
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • CTMX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTKB Health Care
  • CTMX Health Care
  • Exchange
  • CTKB Nasdaq
  • CTMX Nasdaq
  • Market Cap
  • CTKB 430.6M
  • CTMX 380.9M
  • IPO Year
  • CTKB 2021
  • CTMX 2015
  • Fundamental
  • Price
  • CTKB $4.01
  • CTMX $1.91
  • Analyst Decision
  • CTKB Hold
  • CTMX Strong Buy
  • Analyst Count
  • CTKB 4
  • CTMX 3
  • Target Price
  • CTKB $6.00
  • CTMX $5.67
  • AVG Volume (30 Days)
  • CTKB 1.2M
  • CTMX 3.1M
  • Earning Date
  • CTKB 08-06-2025
  • CTMX 08-07-2025
  • Dividend Yield
  • CTKB N/A
  • CTMX N/A
  • EPS Growth
  • CTKB N/A
  • CTMX 263.20
  • EPS
  • CTKB N/A
  • CTMX 0.49
  • Revenue
  • CTKB $196,035,000.00
  • CTMX $141,100,000.00
  • Revenue This Year
  • CTKB $0.74
  • CTMX N/A
  • Revenue Next Year
  • CTKB $7.85
  • CTMX N/A
  • P/E Ratio
  • CTKB N/A
  • CTMX $3.91
  • Revenue Growth
  • CTKB N/A
  • CTMX 18.01
  • 52 Week Low
  • CTKB $2.37
  • CTMX $0.40
  • 52 Week High
  • CTKB $7.63
  • CTMX $3.10
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 59.09
  • CTMX 39.81
  • Support Level
  • CTKB $3.68
  • CTMX $1.72
  • Resistance Level
  • CTKB $4.19
  • CTMX $2.43
  • Average True Range (ATR)
  • CTKB 0.21
  • CTMX 0.20
  • MACD
  • CTKB 0.02
  • CTMX -0.06
  • Stochastic Oscillator
  • CTKB 76.16
  • CTMX 26.84

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: